Company / Cash & Equivalents
Rapport Therapeutics, Inc. Cash & Equivalents History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$56.8M
FY2024
5-year range
$56.8M / $70.2M
FY2023-FY2024
Trend
-19.0%
vs FY2023
Sector context
#176 of 207
Health Care
What the data says
Rapport Therapeutics, Inc.'s cash & equivalents of $57M is lower than 85% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
$57M in FY2024.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 207This company $56.8M Sector average $669.5M
▼
-91.5% below sector average
Key checks
Key Insights
- In FY2024, cash & equivalents decreased 19.0% year-over-year.
- Ranks #176 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 13.36 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $56.8M | -19.0% |
| FY2023 | $70.2M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026